Researchers evaluated the association between baseline LDL-C and treatment with ezetimibe plus statins in post-acute coronary syndrome.
Children diagnosed with type 2 diabetes may face certain health challenges that grow worse over time and follow them into adulthood.
A clinical trial found that more lipid-lowering medications were prescribed when physicians were provided with pictorial information of their patients’ vascular age and carotid plaques.
Avoiding even 1 metabolic syndrome component might decrease the risk for a cardiovascular event or premature death, investigators suggest.
Patients with diabetes achieve LDL-C levels below recommended target goals, but high-intensity statin treatment appears frequently avoided.
The new ACC guideline provides information to clinicians on the management of atherosclerotic cardiovascular disease risk reduction in patients with persistent hypertriglyceridemia.
The researchers wanted to determine the value of LDL-C as a risk biomarker for coronary heart disease, atherosclerotic cardiovascular disease, and stroke events and deaths for people stratified by age.
Cholestene, a dietary supplement marketed for cholesterol management, has been found to contain a hidden drug ingredient, according to the Food and Drug Administration.
HOPE-3 was designed to assess if reducing BP and/or LDL-C would reduce cardiovascular events in study participants at intermediate risk with no prior cardiovascular events.
Investigators report results from MAESTRO-NAFLD-1, a phase 3, randomized, double-blind, placebo-controlled trial evaluating the effect of treatment with resmetirom in patients with hypothyroidism and nonalcoholic steatohepatitis.
This study aimed to assess the effects of the various elements of metabolic syndrome on carotid plaque destabilization.